We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

RVLP RVL Pharmaceuticals PLC

0.00 (0.0%)
Last Updated: 18:00:00
Delayed by 15 minutes


Draw Mode:

Volume 0
Bid Price 0.0225
Ask Price 0.0245
News -
Day High


52 Week Range


Day Low
Share Name Share Symbol Market Stock Type
RVL Pharmaceuticals PLC RVLP NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.0% 0.0282 18:00:00
Open Price Low Price High Price Close Price Previous Close
Trades Shares Traded Average Volume 52 Week Range
0 0 - 0.027 - 1.535
Last Trade Type Quantity Price Currency
- 0 US$ 0.0282 USD

RVL Pharmaceuticals PLC Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
US$ 2.81M - - - -11.76
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

RVL Pharmaceuticals News

Date Time Source News Article
11/27/202305:50GlobeNewswire Inc.RVL Completes Financial Restructuring
11/16/202308:11Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statements
11/01/202315:27Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of..
10/23/202315:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
10/23/202312:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
10/20/202316:00Edgar (US Regulatory)Form 8-K - Current report
10/20/202314:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
10/20/202312:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
10/18/202315:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
10/13/202316:28Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of..
10/13/202315:15Edgar (US Regulatory)Form 8-K - Current report
10/12/202305:50GlobeNewswire Inc.RVL Pharmaceuticals plc Announces Prepackaged Reorganization..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No RVLP Message Board. Create One! See More Posts on RVLP Message Board See More Message Board Posts

Historical RVLP Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.1110.19330.0270.097861344,321,128-0.0828-74.59%
6 Months0.850.880.0270.101687314,799,786-0.8218-96.68%
1 Year1.471.5350.0270.10709836,473,078-1.44-98.08%
3 Years1.252.990.0270.14302853,323,500-1.22-97.74%
5 Years1.252.990.0270.14302853,323,500-1.22-97.74%

RVL Pharmaceuticals Description

RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The Company is currently commercializing UPNEEQ oxymetazoline hydrocholoride ophthalmic solution 0.1% for the treatment of acquired blepharoptosis or low-lying eyelid in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |